Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Public Health and Surveillance

Date Submitted: Jun 9, 2022
Date Accepted: Feb 22, 2023
Date Submitted to PubMed: Feb 22, 2023

The final, peer-reviewed published version of this preprint can be found here:

COVID-19 Vaccine Acceptance and Uptake in Bangkok, Thailand: Cross-sectional Online Survey

Remmel C, Tuli G, Varrelman T, Han A, Angkab P, Kosiyaporn H, Netrpukdee C, Thamarangsi T, Brownstein J, Astley C

COVID-19 Vaccine Acceptance and Uptake in Bangkok, Thailand: Cross-sectional Online Survey

JMIR Public Health Surveill 2023;9:e40186

DOI: 10.2196/40186

PMID: 36811852

PMCID: 10141306

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Covid-19 Vaccine Acceptance and Uptake in Bangkok, Thailand: Cross-Sectional Survey via Social Media

  • Christopher Remmel; 
  • Gaurav Tuli; 
  • Tanner Varrelman; 
  • Aimee Han; 
  • Pakkanan Angkab; 
  • Hathairat Kosiyaporn; 
  • Chanikarn Netrpukdee; 
  • Thaksaphon Thamarangsi; 
  • John Brownstein; 
  • Christina Astley

ABSTRACT

Background:

The third, most severe COVID-19 wave in mid-2021 coincided with dual challenges of limited vaccine supply and lagging acceptance in Bangkok, Thailand. Understanding of persistent vaccine hesitancy during the “608” campaign to vaccinate the over 60 years and eight medical risk groups was needed. On-the ground surveys place further demands on resources and are scale-limited. We leveraged the high Facebook social media use in this densely populated, high-transmission region, together with the University of Maryland COVID-19 Trends and Impact Survey (UMD-CTIS) – a digital health survey conducted among daily Facebook user samples – to fill this need and inform regional vaccine roll-out policy.

Objective:

The aim of this study was to determine the most common reasons for COVID-19 vaccine hesitancy in Bangkok across the vaccine priority groups defined by the “608” campaign, and which sources of COVID-19 information are most trusted and therefore the most effective vehicles for persuading the hesitant.

Methods:

We analyzed 34,423 Bangkok UMD-CTIS surveys June-October 2021. UMD-CTIS demographics and vaccine uptake were consistent with population measures. Vaccine hesitancy, hesitancy reasons, and trusted information sources were compared by 608 priority groups.

Results:

The hesitant were most concerned about vaccination risk-benefits (side effects selected by 63%) over other reasons (not liking vaccines 7%, religious objections 1%) regardless of risk group or time period. Scientists and health experts were most frequently cited as trusted COVID-19 information sources (97%).

Conclusions:

These findings support Bangkok policy measures to address vaccine safety and efficacy concerns through health experts, rather than government or religious officials. Large-scale surveys enabled by existing, widespread digital networks, offer an insightful, minimal-infrastructure resource for informing region-specific health policies needs.


 Citation

Please cite as:

Remmel C, Tuli G, Varrelman T, Han A, Angkab P, Kosiyaporn H, Netrpukdee C, Thamarangsi T, Brownstein J, Astley C

COVID-19 Vaccine Acceptance and Uptake in Bangkok, Thailand: Cross-sectional Online Survey

JMIR Public Health Surveill 2023;9:e40186

DOI: 10.2196/40186

PMID: 36811852

PMCID: 10141306

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.